Establishing UMMC's Clinical Center in NIDDK's Gastroparesis Research Consortium

描述（由申请人提供）： 密西西比大学医学中心提议作为临床中心参加NIDDK的胃轻瘫临床研究联盟。我们的研究团队由医学博士托马斯阿贝尔领导，他在胃轻瘫领域有着悠久的研究历史和临床经验。团队成员包括阿贝尔博士过去曾与之合作的几位主要研究人员，他们共同为胃轻瘫研究提供了一种有价值的多学科方法。 该应用程序的一个主要优势是UMMC提供的潜在研究人群。我们目前正在跟踪大约1,000名胃轻瘫患者。在过去的41个月里，我们已经评估了550名新的胃轻瘫患者，因此平均每年有160名新患者。 UMMC强烈支持在校园内建立临床中心。医疗中心负责卫生事务的副校长和负责研究的副校长承诺提供必要的资源来进行该联盟的研究。 已经提出了两个协议。第一项研究旨在检验以下假设：具有一种或多种重叠综合征的胃轻瘫患者比没有重叠综合征的患者更可能对外周多巴胺阻滞剂有反应。该提案的具体目标是：（1）收集和记录每个研究参与者的重要信息;（2）通过24小时霍尔特心率变异性监测记录研究参与者的基线自主神经状态;（3）为研究参与者提供外周多巴胺阻滞剂多潘立酮的试验;（4）比较具有和不具有重叠综合征的研究参与者对药理学干预的反应;和（5）比较具有血清学自身免疫异常的研究参与者对药理学干预的反应。 第二项研究旨在检验以下假设：固体胃排空延迟患者对临时胃电刺激（GES）的症状反应优于非延迟患者。本提案的具体目标是：（1）为联盟的其他临床中心提供临时GES内镜置入培训;（2）在联盟范围内开展临时GES随机双盲临床试验;（3）比较基线和使用临时GES后的某些标志物;（4）确定两个基线参数，皮肤EGG值和粘膜EGG值，是否可以预测对GES的反应;及（5）根据研究结果，制订指引，以更准确识别最有可能受惠于永久性政府补助计划的人士

DESCRIPTION (provided by applicant): The University of Mississippi Medical Center proposes to participate as a Clinical Center in NIDDK's Gastroparesis Clinical Research Consortium. Our study team is headed by Thomas Abell, MD, who has a long history of research and clinical experience in the area of gastroparesis. Team members include several leading researchers with whom Dr. Abell has collaborated in the past and who, together, provide a valuable multidisciplinary approach to gastroparesis research. A major strength of this application is the potential study population that UMMC has to offer. We are currently following approximately 1,000 patients with gastroparesis. During the past 41 months, we have evaluated 550 new patients for gastroparesis; thus averaging 160 new patients per year. UMMC strongly supports the establishment of a Clinical Center on its campus. The Medical Center's Vice Chancellor for Health Affairs and the Associate Vice Chancellor for Research have committed to providing the resources necessary to conduct the research of the Consortium. Two protocols have been proposed. The first study is designed to test the hypothesis that gastroparesis patients with one or more overlap syndromes are more likely to respond to a peripheral dopamine blocker than patients without overlap syndromes. Specific aims for this proposal are to: (1) collect and record important information about each of the study participants; (2) document study participants' baseline autonomic status through 24-hour holter monitoring of heart rate variability; (3) provide study participants with a trial of the peripheral dopamine blocker, domperidone; (4) compare the response of study participants with and without overlap syndromes to the phamacologic intervention; and (5) compare the response of study participants with serologic autoimmune abnormalities to the phamacologic intervention. The second study is designed to test the hypothesis that patients with delayed solid gastric emptying will have better symptom response to temporary gastric electrical stimulation (GES) than those who are non-delayed. Specific aims for this proposal are to: (1) provide training to the Consortium's other clinical centers in the endoscopic placement of temporary GES; (2) conduct a consortium-wide randomized, double-blind clinical trial of temporary GES; (3) compare certain markers at baseline and after the use of temporary GES; (4) determine whether two of the baseline parameters, cutaneous EGG values and mucosal EGG values, can predict response to GES; and (5) based on the results of the study, develop guidelines to better identify those who would most likely benefit from permanent GES